MDxHealth (NASDAQ:MDXH) Coverage Initiated at Craig Hallum

Stock analysts at Craig Hallum began coverage on shares of MDxHealth (NASDAQ:MDXH - Get Free Report) in a research note issued to investors on Thursday, MarketBeat.com reports. The firm set a "buy" rating and a $8.00 price target on the stock. Craig Hallum's price objective points to a potential upside of 233.33% from the company's previous close.

Separately, Wall Street Zen upgraded MDxHealth to a "hold" rating in a research note on Saturday, May 24th.

MDxHealth Price Performance

Shares of MDxHealth stock traded up $0.13 during trading on Thursday, reaching $2.40. The company's stock had a trading volume of 132,356 shares, compared to its average volume of 91,411. The company has a market capitalization of $113.50 million, a P/E ratio of -2.09 and a beta of 1.31. MDxHealth has a 12-month low of $1.35 and a 12-month high of $3.50. The business has a 50 day moving average price of $2.11 and a 200-day moving average price of $1.87. The company has a quick ratio of 1.92, a current ratio of 2.00 and a debt-to-equity ratio of 13.81.

MDxHealth (NASDAQ:MDXH - Get Free Report) last released its quarterly earnings data on Wednesday, May 14th. The company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.06). The business had revenue of $24.29 million during the quarter, compared to analysts' expectations of $22.62 million. MDxHealth had a negative return on equity of 492.11% and a negative net margin of 41.02%. As a group, sell-side analysts anticipate that MDxHealth will post -1.15 EPS for the current year.

Institutional Trading of MDxHealth

A number of institutional investors and hedge funds have recently modified their holdings of MDXH. FAS Wealth Partners Inc. lifted its stake in MDxHealth by 49.6% during the fourth quarter. FAS Wealth Partners Inc. now owns 24,425 shares of the company's stock worth $58,000 after purchasing an additional 8,100 shares during the period. Geode Capital Management LLC bought a new stake in MDxHealth in the fourth quarter valued at $25,000. XTX Topco Ltd acquired a new position in MDxHealth during the fourth quarter worth $63,000. Castleview Partners LLC bought a new position in shares of MDxHealth during the first quarter valued at $48,000. Finally, Delta Investment Management LLC acquired a new position in MDxHealth in the fourth quarter valued at about $81,000.

About MDxHealth

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.